INKT MiNK Therapeutics
- 0.980
- +0.080+8.89%
MiNK Therapeutics News
MiNK Therapeutics To Sell Securities In Private Placement Financing For $5.8M; Financing Earmarked For Accelerating MiNK-215 Clinical Trials
MiNK Therapeutics To Sell Securities In Private Placement Financing For $5.8M; Financing Earmarked For Accelerating MiNK-215 Clinical Trials
Why MiNK Therapeutics Stock Is Up 11% Monday
MiNK Therapeutics, Inc. (NASDAQ:INKT) shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million.What Happened: On Monday
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures
US stocks look set to open modestly higher in Monday's trading session as investors await key inflation data coming out during the week. Dow Jones Industrial Average futures were up 0.3%, S&P 500 futu
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INK
MiNK Therapeutics Shares Are Trading Higher After the Company Announced Plans to Sell Securities in a Private Placement Financing for $5.8 Million. The Financing Is Earmarked for Accelerating Its MiNK-215 Clinical Trials.
MiNK Therapeutics Shares Are Trading Higher After the Company Announced Plans to Sell Securities in a Private Placement Financing for $5.8 Million. The Financing Is Earmarked for Accelerating Its MiNK
Press Release: MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer -- Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
PDF Version Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKT GKCC, LLC joins as a new investor with Katie Chudnovsky
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
PDF Version NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commer
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
PDF Version MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activ
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
Buy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial Moves
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q4 2023 Earnings Conference
The following is a summary of the MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript:Financial Performance:MiNK Therapeutics ended the year with a cash balance of $3.4 million, boosted by
MiNK Therapeutics Is Maintained at Buy by HC Wainwright & Co.
MiNK Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9
HC Wainwright & Co. analyst Emily Bodnar maintains MiNK Therapeutics with a Buy and lowers the price target from $10 to $9.
Promising Clinical Progress and Market Potential for MiNK Therapeutics' AgenT-797 in Gastric Cancer Study
MiNK Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 900.22% HC Wainwright & Co. $10 → $9 Maintains Buy 08/10/2023 1011.36% HC Wainwright & Co. → $1
MiNK Therapeutics Q4 EPS $(0.16) Misses $(0.15) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 30.43 percent increase over losses of $
MiNK Therapeutics 4Q EPS 16c >INKT
MiNK Therapeutics 4Q EPS 16c >INKT
Analysis
Price Target
No Data
